GLOW
Not medical advice
Describes a named combination people search for — not a prescription. See the Disclaimer.
What It Is
“GLOW” is the popular name for a three-peptide blend marketed for skin appearance plus tissue healing — the Skin & Hair “glow” angle layered on top of soft-tissue Recovery and Joint & Tendon Repair. It combines:
- GHK-Cu — a copper-binding tripeptide with real (small) topical cosmetic data for collagen/skin remodeling; the “glow” component.
- BPC-157 — a synthetic pentadecapeptide studied (mostly in rodents) for soft-tissue and gut healing.
- TB-500 — a Thymosin Beta-4 fragment studied in animal/cell models for cell migration and repair.
It is most often sold pre-mixed in a single vial, commonly weighted heavily toward GHK-Cu (a frequently reported blend is ~50 mg GHK-Cu : 10 mg TB-500 : 10 mg BPC-157, a 5:1:1 ratio).
Why People Combine These
The rationale is layering complementary proposed effects:
- GHK-Cu brings the skin-remodeling/collagen angle (its best-supported, topical use).
- BPC-157 + TB-500 bring the Wolverine Stack soft-tissue repair rationale.
- Together they are marketed as “look and heal better” — cosmetic plus regenerative — in one injection.
Evidence strength
No published human trial has tested these three together. GHK-Cu has small human cosmetic (topical) evidence; BPC-157 and TB-500 are Preclinical; the combination as an injectable is Anecdotal. Note that GHK-Cu’s strongest evidence is topical, while GLOW is typically injected — a route with far less data. See Side Effects & Risk Management.
Reported Dosing
As reported, not advice
Protocols below are as reported in community/vendor sources for a pre-mixed blend, not a clinical regimen. There is no established human therapeutic dose. See Reconstitution & Dosing Math and Cycling.
| Component | Reported dose | Frequency | Notes |
|---|---|---|---|
| Total GLOW blend | ~2.3 mg total/day | 1× daily (SC), ~4 weeks | E.g. ~0.10 mL of a 23.3 mg/mL reconstitution |
| GHK-Cu (in blend) | ~1.7 mg/day | 1× daily | The bulk of the blend (5:1:1) |
| BPC-157 (in blend) | ~0.33 mg/day | 1× daily | Per-peptide share of the daily dose |
| TB-500 (in blend) | ~0.33 mg/day | 1× daily | Per-peptide share of the daily dose |
Reported cycles run roughly 4 weeks on, then a 2–4 week break to assess. Some also use GHK-Cu topically alongside (its evidence-backed route). See Cycling.
Combined Risks & Considerations
- Three-peptide uncertainty. Stacking three compounds with limited (injectable) human safety data compounds the unknowns.
- Copper load. Repeated systemic GHK-Cu raises a theoretical copper-accumulation concern not well studied in humans — relevant because GLOW is dosed daily.
- Pro-angiogenic profile. All three have pro-angiogenic/remodeling activity in preclinical work; the speculative tumor-growth concern applies and is uncharacterized in humans.
- WADA-banned component. TB-500 is prohibited in sport (S2); tested athletes risk sanctions.
- Sourcing risk is amplified by pre-mixing (see below).
- See Side Effects & Risk Management.
Sourcing
GLOW is almost always sold pre-mixed, so you cannot independently confirm each peptide’s identity, the stated ratio, or fill weight — and the GHK-Cu copper content and TB-500 fragment-vs-protein ambiguity are hidden inside the mix. Before trusting any product:
- Vet the market and vendors: Sourcing
- Read the certificate of analysis: How to Read a CoA
- Watch for warning signs: Red Flags & Scams
No vendors are endorsed here.
FAQ
Is GLOW FDA-approved? No. None of the components is approved for injectable human use; GHK-Cu is permitted only as a topical cosmetic ingredient.
Does the “glow” come from GHK-Cu? That is the marketed idea — GHK-Cu drives the skin/collagen angle. Its supportive human data is for topical use, not injection.
How is GLOW different from KLOW? KLOW is GLOW plus the anti-inflammatory tripeptide KPV.
Can I use GHK-Cu topically instead? Topical GHK-Cu is its evidence-backed route for skin; many people use it that way separately. See GHK-Cu.
References
- Pickart L., Margolina A. (2018). “Regenerative and protective actions of the GHK-Cu peptide.” International Journal of Molecular Sciences.
- Maquart F.X. et al. (1988). “Stimulation of collagen synthesis by the tripeptide-copper complex GHK-Cu²⁺.” FEBS Letters.
- Gwyer D., Wragg N.M., Wilson S.L. (2019). “Gastric pentadecapeptide BPC 157 and soft tissue healing.” Cell and Tissue Research.
- Goldstein A.L. et al. (2005). “Thymosin β4: actin-sequestering protein moonlights to repair injured tissues.” Trends in Molecular Medicine.
← Stacks · Home Educational information only — not medical advice. See Disclaimer.